Dr. Richard Cathomas, medical oncologist from Zurich in Switzerland discusses Immunotherapy in muscle-invasive bladder cancer.

He goes into the mechanism of action of immunotherapy and why could it work well in bladder cancer. 
Where do we currently stand with the use of immunotherapy in the NEOADJUVANT setting of muscle invasive bladder cancer? And what is currently the best place to integrate immunotherapy for METASTATIC bladder cancer?

Prof. Dr.  Cathomas closes with the answer to the question of why some patients benefit much more than others from immunotherapy. 

Prof. Dr. Richard Cathomas is oncologist panel member on the EAU Guidelines for muscle-invasive bladder cancer.